Well see you again next week
2 Moreover, the analysis showed an increase in weight loss across all members in the program, including those who did and did not persist with GLP-1s for the entire year, with an average 16.3% weight loss 1 nearly twice the amount observed in the real world analysis
Source: Lopez-Otin, C., Galluzzi, L., Freije, J
As with all components here, human clinical data are limited and the mechanisms are described in a research context only
Garetosmab, activin A inhibitor antibody for muscle-preservation combination regimens in obesity Recent Highlights: In June 2026, the company announced it would present new clinical data from the Phase 2 COURAGE trial that examines the effects of trevogrumab (anti-GDF8) on lean mass in people with obesity treated with semaglutide
What to actually do about it Here's the protocol I walk my GLP 1 patients through: 1